Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 1, 2009, Pages 19-26

  Tamaro, Ilaria ^a   Genazzani, Armando ^a   Canonico, Pierluigi ^a   Grosa, Giorgio ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Anticancer drugs; CYP; Drug interactions; Human liver microsomes; Rabeprazole

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FLUOXETINE; GEMCITABINE; METHOTREXATE; ONDANSETRON; RABEPRAZOLE;

ACCURACY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SCREENING; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LINEAR SYSTEM; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 65649153761     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191379     Document Type: Article

References (17)

1. Ishizaki T., Horai Y. (1999). Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther., 13, 27-36.
2. Yasuda S., Horai Y., Tomono Y., Nokai H., Yamato C., Manabe K., Kobayashi K., Chiba K., Ishizaki T. (1995). Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Therapy, 58, 143-154.
3. VandenBranden M., Ring B.J., Binkley S.N., Wrighton S.A. (1996). Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics, 6, 81-91.
4. Klotz U. (2000). Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet., 38, 243-270.
5. Royer I., Monsarrat B., Sonnier M., Wright M, Cresteil T. (1996). Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res., 56, 58-65.
6. Vaclavikova R., Soucek P., Svobodova L., Anzenbacher P., Simek P., Guengerich F.P., Gut I. (2004). Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab. Dispos., 32, 666-74.
7. Relling M.V., Nemec J., Schuetz E.G. Schuetz J.D., Gonzalez F.J., Korzekwa K.R. (1994). O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45, 352-358.
8. Kawashiro T., Yamashita K., Zhao X.J., Koyama E., Tani M., Chiba K., Ishizaki T. (1998). A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J. Pharmacol. Exp. Ther., 286, 1294-1300.
9. Chang T.K.H., Weber G.F., Crespi C.L., Waxman D.J. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3 A in human liver microsomes. Cancer Res., 53, 5629-5637
10. Ren S., Yang J.S., Kalhorn T.F., Slattery J.T. (1997). Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide in human liver microsomes. Cancer Res., 57, 4229-4235.
11. Huang Z., Roy P., Waxman D.J. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol., 59, 961-972.
12. Mandrioli R., Cantelli Forti G., Raggi M.A., (2006). Fluoxetine Metabolism and Pharmacological Interactions: The Role of Cytochrome P450. Curr. Drug Metab., 7, 127-133 and references cited herein.
13. Dixon C.M., Colthup P.V., Serabjit-Singh C.J., Kerr B.M., Boehlert C.C., Park G.R., Tarbit M.H. (1995). Multiple forms of cytochrome P450 are involved in metabolism of ondansetron in humans. Drug Metab. Dispos., 23, 1225-1230.
14. Chladek J., Martinkova J., Sispera L. (1997). An in vitro study on methotrexate hydroxylation in rat and human liver. Physiol. Res., 46, 371-379.
15. Diasio R.B., Harris B.E. (1989). Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16, 215-37.
16. Giovannetti E., Mey V., Loni L., Nannizzi S., Barsanti G., Savarino G., Ricciardi S., Del Tacca M., Danesi R. (2007). Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol. Res., 55, 343-349.
17. De Jong J., Geijssen G.J., Munniksma C.N., Vermorken J.B., Van der Vijgh W.J. (1992): Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-1-leucyldoxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol., 10, 1897-1906.